Stay on top of the latest CAR T-cell therapy developments
CAR T-cell therapy is regarded as a revolutionary cancer therapy; the curative potential of the CAR T-cell therapies represents a paradigm shift in cancer treatment.
The landmark approvals of Kymriah and Yescarta in 2017 in the United States, their geographic expansion over 2018-2019 in Europe and Japan, and their slow but steadily increasing worldwide sales have encouraged investors to support development in the field of adoptive cellular immunotherapy.
Over the last couple of years, there have been rapid advancements in the field. Researchers are fine-tuning the safety and efficacy profiles of CAR T cells with novel concepts and technologies. These will be therapies that address current uptake challenges through superior efficacy, safety, and delivery mechanisms.
In the charts below, Our Oncology experts provide a view of where the market is heading, and which companies are leading the charge.
“Using CAR T-cells in multiple myeloma is interesting because, currently, myeloma is incurable. We have a lot of drugs that can induce remission but cannot cure the patient. CAR T-cells will probably get moved from the refractory patients to earlier stages of therapy, as a way of consolidating the remission and aiming for a cure.”
– Hematologist-oncologist, Italy
“There is a race to find a CAR T-cell therapy for solid tumors, but that is probably a long road. There are physical barriers in solid tumors, so getting into the tumor mass is a problem. But the main problem seems to be in the microenvironment which is immunosuppressive.”
– Hematologist-oncologist, United Kingdom
Principal Director and Team Lead, Oncology
Pricipal Analyst, Oncology